This story is from August 16, 2017
USFDA EIR to Granules Gagillapur plant
Hyderabad: City-based pharma player
Granules
India Ltd informed the bourses on Wednesday that it has received the Establishment Inspection Report (EIR) from the US drug watchdog, US Food & Drug Administration, for its Gagillapur facility located in Hyderabad.Popular from Business
- Stock market crash today: BSE Sensex ends 1,190 points down; Nifty50 below 23,950 - top reasons markets tanked
- High-speed 280 kmph trains soon! Indian Railways to manufacture bullet trains - check top features
- No need to apply, you will get e-version of PAN in mail ID
- Amway India loss doubles to Rs 52.78 cr in FY24, sales flat at Rs 1,284 cr
- DBS India launches wealth management with access to six markets
end of article
Trending Stories
- PAN 2.0 FAQs answered! Will your PAN Card change, will it have a new number? Income Tax Department releases top points
- What is PAN 2.0 project & will you have to apply for a new PAN Card with QR code?
- This billionaire American CEO thinks you may work just 3.5 days a week in future
- Top Fixed Deposit Rates: These bank FDs will earn you up to 9% return for 3-year deposits - check list
- ‘Mr Modi is fantastic…’: Prem Watsa, known as ‘Canada’s Warren Buffett’, says India can grow at 10% under PM Modi
- How RBI’s gold buying is helping shore up India’s foreign exchange reserves
- Booking a train ticket? New Indian Railways train ticket reservation rules effective from November 1 - check details
Visual Stories
- NEET UG 2024 result awaited: Top 10 NIRF-ranked medical colleges of India
- 7 New Expected Bullet Train Routes in India
- 10 Upcoming High-Speed Expressways That Will Change Highway Travel In India
- 8 Transformational Indian Railways Projects You Shouldn’t Miss
- Why Sensex, Nifty50 Hit New Highs, M-Cap At $5 Trillion: Top Reasons
TOP TRENDS
UP NEXT
Start a Conversation
Post comment